- Home
- AKTX vs ZTG Comparison
AKTX vs ZTG Comparison
Compare AKTX & ZTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKTX | ZTG |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Macau |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 20.4M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AKTX | ZTG |
|---|---|---|
| Price | $11.33 | N/A |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $33.50 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | N/A |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | N/A |
| 52 Week High | $29.32 | N/A |
Technical Indicators
Market Signals| Indicator | AKTX | ZTG |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | N/A |
| Support Level | $0.32 | N/A |
| Resistance Level | $29.32 | N/A |
| Average True Range (ATR) | 1.94 | 0.00 |
| MACD | -0.78 | 0.00 |
| Stochastic Oscillator | 5.40 | 0.00 |
Price Performance
Historical ComparisonAbout AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.